Child Tax Credit and Labor Force Participation of Women

– William Monkman, student

The Child Tax Credit (CTC) has recently increased: the 2017 Tax Cut and Jobs Act doubled the CTC from $1,000 to $2,000 per child and entitled parents whose federal liabilities are less than their CTC to receive an additional $1,400. The CTC, in terms of its share in income, is relatively worth more to low-income earners than high-income earners. Because of the additional $1,400, it can even be argued as a progressive subsidy. Continue reading

Who Benefits from Healthcare Reform?

– Aaron Hansen, student

The Affordable Care Act (ACA) has been the topic of debates and political rhetoric quite a bit in the past 18 months. Our national government has been working to replace the ACA and scale back the federal regulations that came along with it. It is a hot button topic and a confusing one. Let us examine two questions so that we might better understand the motivations of future proposals. Who is healthcare reform for? Who drives the policy changes? Continue reading

Ban the Box

Hibaq Abdullahi, student

In the United States, individuals with criminal histories will regularly experience re-arrest, reconviction, resentencing, or return to prison after their first conviction. This phenomenon, known as recidivism, represents an enormous financial burden to society in the form of lost wages and the costs of incarceration; one 1994 study of 15 states found recidivism rates over 66% in as little as three years after release from prison. Attempts to reduce recidivism often focus on employment opportunities: the difficulty that former convicts face in getting a job may explain their propensity to repeat criminal activity. Continue reading

The FDA’s Approval Process: Too Much of a Good Thing?

– David Kind, student

A vigilant agency may take extra time in its approval process to ensure the safety and efficacy of a drug. However, the extra time comes at the cost lives that could have been saved provided that the drugs were approved faster. How can the FDA find a balance between the two?

Continue reading